Feb 10, 2026 8:30 am EDT Evommune EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis
Sep 19, 2025 7:30 am EDT EADV Late-Breaker Presentation of EVO756 Phase 2 Data in Chronic Inducible Urticaria
